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Background: Premature myocardial infarction with life-threatening complications may become 
epidemic in some Asian and African countries and especially Iran. Fibrinogen is considered as 
one of the probable risk factors of myocardial infarction. The aim of our study was to assess 
fibrinogen levels as an etiology of premature myocardial infarction in young Iranian men.
Findings: A case-control study was conducted between May 2005 and May 2007 to investigate 
the association between serum total fibrinogen level and myocardial infarction in men aged 
younger than 55 years admitted to the cardiac care units of Peymanieh and Motahari Hospitals 
affiliated to Jahrom University of Medical Sciences, Iran. The mean age of patients was 45.2 ± 4 
years in patients with premature myocardial infarction and 47.06 ± 4.5 years in the control group 
(p = 0.085). There were no statistically significant relationships between the two groups in history 
of premature myocardial infarction in their first-degree relatives (p = 0.05), cigarette smoking 
(p = 0.46), diabetes (p = 0.49), or hypertension (p = 1). The mean plasma fibrinogen in patients 
(354.9 ± 60 mg/dL) was elevated markedly compared with the control group (329 ± 73 mg/dL). 
Hyperfibrinogenemia (340 mg/dL) was detected in 81.8% of patients and 57.5% of controls 
(95% confidence interval, odds ratio = 3.3; p = 0.036).
Conclusion: This study introduced fibrinogen as a risk factor for premature coronary artery 
disease in Iranian men.
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Background
The notion that fibrinogen is related to cardiovascular diseases was first aired in the 
1950s,1 when its level was found to be increased in patients with ischemic heart disease. 
During recent years, many prospective epidemiological studies have reported positive 
associations between the risk of coronary heart disease (CHD) and plasma fibrinogen 
levels.2–5 Fibrinogen is the major coagulation protein in blood by mass, the precursor 
of fibrin, and an important determinant of blood viscosity and platelet aggregation.6–9 
Because fibrinogen levels can be reduced considerably by lifestyle interventions that 
also affect levels of established risk factors (such as regular exercise, smoking cessation, 
and moderate alcohol consumption), there is interest in the possibility that measurement 
(or modification) of fibrinogen may help in disease prediction or prevention.6–8,10
Furthermore there are few studies evaluating the role of fibrinogen in premature 
myocardial infarction (MI) as an independent risk factor for developing coronary artery 
disease. Iran is a developing country with a high and growing prevalence of coronary 
artery disease. The incidence of acute coronary syndromes during recent years has 
increased surprisingly, especially among young Iranian men.Vascular Health and Risk Management 2009:5 674
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In the present study we examined the relation between 
serum total fibrinogen concentration and premature MI in 
Iranian patients to further elucidate the role of fibrinogen as 
an independent risk factor for acute CHD events.
Methods
Study design
A case-control study was conducted between May 
2005 and May 2007 to investigate the association 
between serum fibrinogen level and MI in men aged younger 
than 55 years admitted to the cardiac care units of Peymanieh 
and Motahari Hospitals affiliated to the Jahrom University of 
Medical Sciences, Iran. The diagnosis of acute myocardial 
infarction (AMI) was based on the presence of ischemic chest 
pain of at least 30 minutes’ duration and creatine kinase (CK) 
elevation of at least twice the upper normal limit, with CK, 
muscle and brain (CK-MB) isoenzyme concentration of at 
least 6% of the peak CK value, accompanied by dynamic 
ST-segment elevation or depression of 1 mm or more in 
at least two adjacent leads. Premature AMI was defined as 
having the above-mentioned criteria in patients aged younger 
than 55 years.
Patients and controls that had hyperlipidemia were 
excluded from the study. At that time the patients were 
considered to be in a stable clinical and metabolic state and 
not in an acute phase for plasma fibrinogen.11
Among 200 men with a first episode of AMI who were 
admitted within 12 hours of symptoms onset, 33 were 
enrolled as cases. None of these 33 patients had recurrent MI 
during their follow up and all of them completed the study. 
Controls were 33 men aged under 55 years who survived to 
the end of the study period free from incident MI and stroke. 
They were randomly selected with frequency matching to 
cases by the site of residence and by age group. They also 
were matched with case group regarding other CHD risk 
factors such as diabetes mellitus, hypertension, and cigarette 
smoking. Participating case and control subjects were asked 
to complete a questionnaire to obtain information on any 
history of known or suspected cardiovascular risk factors, 
including physician-diagnosed diabetes, hypertension, or 
high cholesterol, cigarette smoking, height and weight, 
alcohol consumption, physical activity, history of MI in 
first-degree relatives and demographic characteristics.
Blood collection and laboratory 
methods
To determine fibrinogen, we obtained a 1.8-mL venous 
blood specimen after a 12-hour fast from 33 MI case subjects 
and 33 control subjects into vacuum tubes containing 
0.2 mol/L trisodium citrate (9:1 blood/citrate, vol/vol). The 
blood was centrifuged immediately for about 15 minutes 
and the obtained plasma was then frozen at −20 °C. Case 
blood samples were obtained at least one year after the 
MI. Plasma fibrinogen level was determined using TEClot 
Fib Kit-10 (Lot No: 500502; TECO GmbH, Neufahrn, 
Germany). A serum fibrinogen level more than 340 mg/dL 
was considered high. The study was approved by the local 
ethics committee of each hospital and each patient gave 
their written informed consent. This study was conducted 
in accordance with the Declaration of Helsinki.
Statistical analysis
Data were collected and analyzed using SPSS software 
(SPSS Inc., Chicago, IL, USA). A p value of less than 0.05 
was considered significant. Comparisons of frequencies 
have been carried out using χ2 tests or Fisher’s exact test as 
appropriate. The research council of Jahrom University of 
Medical Sciences supported our data collection and helped 
purchase the required equipment.
Results
The mean age of our case and control subjects was 
45.2 ± 4 years and 47.06 ± 4.5 years, respectively 
(p = 0.085). Among patients with premature AMI, seven 
(21.2%) had history of premature MI in their first-degree 
relatives whereas six control subjects (18.02%) had family 
history of premature AMI (p = 0.05). 18 patients (54.5%) 
and 15 control subjects (45.4%) were cigarette smokers 
(p = 0.46). Two patients were diabetic (6.1%), but none of 
the control group were diabetic (p = 0.49). In both case and 
control groups, five individuals (15.2%) had hypertension 
(p = 1) (Table 1).
Twenty-seven patients (81.8%) had elevated fibrinogen 
levels (340 mg/dL). In 33 control group individuals, 
19 (57.5%) had elevated fibrinogen levels (odds ratio 
[OR] = 3.3). The plasma fibrinogen level was significantly 
Table 1 cHD risk factors in case and control groups
Case Control P-value
Age (year) 45.2 ± 4 47.06 ± 4.5 nS
cigarette smoking 18 15 nS
Diabetes mellitus 2 0 nS
Hypertension 5 5 nS
Family history of premature Mi 7 6 nS
Abbreviations: cHD, coronary heart disease; Mi, myocardial infarction; nS, not 
statistically significant.Vascular Health and Risk Management 2009:5 675
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higher in case subjects than in the control group (p = 0.036) 
(Table 2).
Discussion
The present study implies that high serum fibrinogen levels 
are a risk factor for premature AMI. As described earlier, 
for this study we prepared venous samples for detection of 
fibrinogen levels one year after MI to show that fibrinogen 
concentrations return to basal levels. Using this method 
there was no need to store serum samples for a long period 
of time and the potential bias existing in case control studies 
about falsely elevated levels of fibrinogen after MI would 
diminish.
We obtained venous blood specimen from both case 
and control groups after a 12-hour fast to eliminate the 
probable effect of diet on fibrinogen levels. Both case and 
control groups were matched regarding other risk factors 
of coronary artery disease such as hypertension, diabetes 
mellitus, cigarette smoking, hyperlipidemia, age, sex, and 
body mass index. Several prospective and cross-sectional 
studies have revealed that plasma fibrinogen levels have 
a strong predictive value for CHD and stroke. In a large, 
population-based, prospective study, the Atherosclerosis 
Risk in Communities (ARIC) Study, plasma fibrinogen was 
found to be an important risk factor for CHD in women.12 
In an Iranian study performed in 2007, serum fibrinogen 
levels were significantly higher in patients with AMI with 
ST-change.13 Other studies are in favor of the hypothesis 
of a multifactorial etiology of CHD in young patients 
suffering MI.14
The physiological importance of elevated plasma 
fibrinogen levels is not fully understood. The mechanisms by 
which plasma fibrinogen may be involved in atherothrombosis 
are theological alterations, increased platelet aggregation 
tendency, increased fibrin formation, and stimulation of 
vascular cell proliferation and migration, with increasing 
plasma fibrinogen levels.15 Thus, elevated plasma fibrinogen 
levels, whatever their origin – genetic, as part of an 
inflammation reaction, or some other reason – may cause 
a hypercoagulative state that could influence the degree 
and duration of thrombus formation at the time of coronary 
injury.
Elevated fibrinogen concentrations could be due to 
the disease (ie, MI) or to an underlying vascular disease 
(eg, atherosclerosis) rather than as a cause of MI or vascular 
disease. It is possible that because serum has often been 
stored for a considerable period of time, the measurement of 
serum levels of fibrinogen may be compromised.
This study was conducted among male patients and the 
sample size is relatively low. Further studies on the role of 
fibrinogen in acute coronary syndromes in other age groups 
and sexes are necessary.
The role of plasma fibrinogen levels in premature coronary 
artery disease is less clear. The prevalence of cardiovascular 
disease especially among the youth is growing in Iran and 
further investigations for finding risk factors in the Iranian 
population seem to be of great importance.
Our findings suggested that higher fibrinogen levels are 
associated with premature coronary artery disease in the 
Iranian population.
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